Etodolac ext-rel Tablets Rx
Generic Name and Formulations:
Etodolac 400mg, 500mg, 600mg; ext rel tabs.
Various generic manufacturers
Indications for Etodolac ext-rel Tablets:
Osteoarthritis. Rheumatoid arthritis. Juvenile rheumatoid arthritis (JRA).
Use lowest effective dose for shortest duration. Initially 400–1000mg once daily.
<6yrs: not established. Use lowest effective dose for shortest duration. Give once daily. JRA: 6–16yrs (20–30kg): 400mg; (31–45kg): 600mg; (46–60kg): 800mg; (>60kg): 1000mg.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Advanced renal disease: not recommended. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic and renal function in long-term therapy. Pre-existing asthma. Discontinue at 1st sign of rash or any other hypersensitivity. Renal or hepatic impairment. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C; 3rd trimester: avoid). Nursing mothers: not recommended.
NSAID (pyranocarboxylic acid deriv.).
Avoid concomitant aspirin, salicylates, phenylbutazone, or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. May cause false (+) urinary bilirubin test.
GI upset, dizziness, headache, rash (may be severe), anemia, edema, pruritus, tinnitus; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions.
Formerly known under the brand names Lodine (caps, tabs); Lodine XL (ext-rel tabs).
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis